These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12894712)

  • 41. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
    Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
    Hirao K; Kawamoto H; Sakakihara I; Noma Y; Yamamoto N; Harada R; Tsutsumi K; Fujii M; Kato H; Kurihara N; Mizuno O; Ogawa T; Ishida E; Yamamoto K
    Int J Clin Oncol; 2011 Dec; 16(6):637-45. PubMed ID: 21519814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 48. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
    Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
    Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.
    Blackstock AW; Bernard SA; Richards F; Eagle KS; Case LD; Poole ME; Savage PD; Tepper JE
    J Clin Oncol; 1999 Jul; 17(7):2208-12. PubMed ID: 10561277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
    Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
    Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
    Park JS; Oh SY; Kim SH; Kwon HC; Kim JS; Jin-Kim H; Kim YH
    Jpn J Clin Oncol; 2005 Feb; 35(2):68-73. PubMed ID: 15709089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
    Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
    Jin SF; Fan ZK; Pan L; Jin LM
    Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
    Icli F; Akbulut H; Utkan G; Yalcin B; Dincol D; Isikdogan A; Demirkazik A; Onur H; Cay F; Büyükcelik A
    J Surg Oncol; 2007 May; 95(6):507-12. PubMed ID: 17192920
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.